Literature DB >> 12727622

Activation of rheumatoid factor (RF) B cells and somatic hypermutation outside of germinal centers in autoimmune-prone MRL/lpr mice.

Mark J Shlomchik1, Chad W Euler, Sean C Christensen, Jacqueline William.   

Abstract

Two critical questions need to be answered concerning the origins of autoreactive B cells in autoimmunity. First, how are autoreactive B cells regulated in normal situations? Second, how do such B cells escape tolerance mechanisms during autoimmunity? To address these questions, an Ig transgenic (Tg) mouse system based on the rheumatoid factor (RF) specificity has been developed. Tg mice express either the H or both H and L chains from AM14, an MRL/lpr-derived RF. Using this system, it was first shown that RF B cells are neither tolerized nor activated in a normal mouse. New insights into the timing and sites of initial RF B cell activation in MRL/lpr mice have been gained recently. RF B cells are activated. It was found, unexpectedly, that RF B cell activation, somatic hypermutation, and selection take place outside of the germinal center. We discuss the implications of this for the regulation of autoreactive B cells as well as for the regulation of hypermutation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727622     DOI: 10.1111/j.1749-6632.2003.tb06031.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice.

Authors:  Rachel A Henry; Peggy L Kendall
Journal:  J Immunol       Date:  2010-06-23       Impact factor: 5.422

2.  Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.

Authors:  Yanwei Wu; Shijun He; Bingxin Bai; Luyao Zhang; Lu Xue; Zemin Lin; Xiaoqian Yang; Fenghua Zhu; Peilan He; Wei Tang; Jianping Zuo
Journal:  Cell Mol Immunol       Date:  2015-03-16       Impact factor: 11.530

3.  The lupus-prone NZM2410/NZW strain-derived Sle1b sublocus alters the germinal center checkpoint in female mice in a B cell-intrinsic manner.

Authors:  Eric B Wong; Tahsin N Khan; Chandra Mohan; Ziaur S M Rahman
Journal:  J Immunol       Date:  2012-11-09       Impact factor: 5.422

4.  Spontaneous loss of tolerance of autoreactive B cells in Act1-deficient rheumatoid factor transgenic mice.

Authors:  Natalia V Giltiay; Yi Lu; Jaime L Cullen; Trine N Jørgensen; Mark J Shlomchik; Xiaoxia Li
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

5.  Rheumatoid factors induce signaling from B cells, leading to Epstein-Barr virus and B-cell activation.

Authors:  Lixin Yang; Masayuki Hakoda; Kazuya Iwabuchi; Tsuyoshi Takeda; Takao Koike; Naoyuki Kamatani; Kenzo Takada
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 6.  B-cell anergy: from transgenic models to naturally occurring anergic B cells?

Authors:  John C Cambier; Stephen B Gauld; Kevin T Merrell; Barbara J Vilen
Journal:  Nat Rev Immunol       Date:  2007-07-20       Impact factor: 53.106

7.  Evidence for selective transformation of autoreactive immature plasma cells in mice deficient in Fasl.

Authors:  Jian Qiao Zhang; Cheryl Okumura; Thomas McCarty; Min Sun Shin; Partha Mukhopadhyay; Mitsuo Hori; Ted A Torrey; Zohreh Naghashfar; Jeff X Zhou; Chang Hoon Lee; Derry C Roopenian; Herbert C Morse; Wendy F Davidson
Journal:  J Exp Med       Date:  2004-12-06       Impact factor: 14.307

8.  Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction.

Authors:  Anthony C Cruz; Madhu Ramaswamy; Claudia Ouyang; Christopher A Klebanoff; Prabuddha Sengupta; Tori N Yamamoto; Françoise Meylan; Stacy K Thomas; Nathan Richoz; Robert Eil; Susan Price; Rafael Casellas; V Koneti Rao; Jennifer Lippincott-Schwartz; Nicholas P Restifo; Richard M Siegel
Journal:  Nat Commun       Date:  2016-12-23       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.